FEops closes a € 1.3M series A financing round to commercialise its TAVIguide™ service
Ghent, Belgium: 19 January 2015 - FEops, a pioneer in the field of patient-specific 3D simulations for cardiovascular interventions, is pleased to announce the closing of a € 1.3 million series A financing round, led by Capricorn Venture Partners and PMV. The funding will be used to support the launch of FEops' first product, TAVIguideTM, in key markets in Europe and the US. TAVIguideTM is a cloud based pre-operative planning service for Transcatheter Aortic Valve Implantation (TAVI). Part of the proceeds will be dedicated to advance clinical development of the technology and diversify the pre-operative planning services offered to include additional cardiovascular interventions.
Next > Green Biologics secures $76 million in debt and equity financing
Previous > Freeslate integrates the DropSense96TM for Biologics Quantification on its Biologics Formulation System